학술논문
Low-Dose Decitabine (DAC), Alone or in Combination with All-Trans Retinoic Acid (ATRA), Is An Active First-Line Treatment in Older AML Patients of All Cytogenetic Risk Groups: Final Results of the FR00331 Multicenter Phase II Study.
Document Type
Abstract
Author
Source
In Blood 20 November 2009 114(22):4141-4141
Subject
Language
ISSN
0006-4971